|
|
|
|
|
|
| MARKET RESEARCH SECTOR IN FOCUS | |
|
|
|
|
|
|
| SEARCH RESULTS |
|
Search Criteria:
Title: inhibitors
Published Date Range : Any Date
| Page: 1 |
Found total 29 records. |
|
|
| Title |
Published  |
Price |
| Corrosion Inhibitors to 2017 |
Mar, 2013 |
$ 5,100.00
|
|
| Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors |
Feb, 2013 |
$ 2,000.00
|
|
| Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth |
Jan, 2013 |
$ 3,500.00
|
|
| The World Market for Antiknock Preparations, Oxidation Inhibitors, Anticorrosive Preparations, and Other Prepared Additives for Mineral Oils Including Gasoline: A 2013 Global Trade Perspective |
Jan, 2013 |
$ 595.00
|
|
| The 2013 World Forecasts of Antiknock Preparations, Oxidation Inhibitors, Anticorrosive Preparations, and Other Prepared Additives for Mineral Oils Including Gasoline Export Supplies |
Jan, 2013 |
$ 325.00
|
|
| The Next Wave In Cancer Treatment - Kinase Inhibitors |
Dec, 2012 |
$ 2,500.00
|
|
| Global Kinase Inhibitors Market 2011-2015 |
Nov, 2012 |
$ 1,500.00
|
|
| Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives |
Oct, 2012 |
$ 3,500.00
|
|
| Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists |
Oct, 2012 |
$ 192.82
|
|
| Global Enzyme Inhibitors Market 2011-2015 |
Sep, 2012 |
$ 1,500.00
|
|
| Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline |
Jul, 2012 |
$ 3,500.00
|
|
| Global Markets for Enzyme Inhibitors - Focus on Europe |
Jun, 2012 |
$ 4,400.00
|
|
| Global Markets for Enzyme Inhibitors - Focus on the US |
Jun, 2012 |
$ 4,400.00
|
|
| Global Markets for Enzyme Inhibitors - Focus on Emerging Markets |
Jun, 2012 |
$ 4,400.00
|
|
| Global Markets for Enzyme Inhibitors |
Jun, 2012 |
$ 5,450.00
|
|
| Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications |
May, 2012 |
$ 3,500.00
|
|
| Hepatitis C Virus Infection: Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next? |
Apr, 2012 |
$ 2,000.00
|
|
| Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists |
Feb, 2012 |
$ 3,500.00
|
|
| Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market |
Oct, 2011 |
$ 3,500.00
|
|
| Competitor Analysis: Novel Mitotic Kinase Inhibitors |
Sep, 2011 |
$ 514.18
|
|
| Competitor Analysis: HDAC Inhibitors |
Jul, 2011 |
$ 514.18
|
|
| Competitor Analysis: PI3K-AKT-mTOR Inhibitors |
Jun, 2011 |
$ 642.73
|
|
| Competitor Analysis : Ras-Raf-MEK-ERK Inhibitors |
Jun, 2011 |
$ 578.45
|
|
| GLOBAL CORROSION INHIBITORS - water & oil based, Organic & Inorganic Type, Applications, Raw materials Trends and Forecasts (2010 - 2015) |
Mar, 2011 |
$ 4,650.00
|
|
| Telaprevir and Boceprevir: The First Generation Protease Inhibitors Boosts Response Rates to Standard Chronic Hepatitis C Treatment |
Mar, 2011 |
$ 500.00
|
|
| Tivozanib: Newer VEGF Inhibitors Represent A Paradigm Shift In Renal Cell Carcinoma Therapy |
Feb, 2011 |
$ 500.00
|
|
| The 2011-2016 Outlook for Scale Inhibitors in Greater China |
Jan, 2011 |
$ 495.00
|
|
| The 2011-2016 Outlook for Small Molecule Kinase Inhibitors in Greater China |
Jan, 2011 |
$ 495.00
|
|
| The 2011-2016 Outlook for Corrosion Inhibitors in Greater China |
Jan, 2011 |
$ 495.00
|
|
Page: 1
Go To Advance Search
|
|
|
|
0 items in cart
